Ozone Therapy and EBOO/RHP
Extra-corporeal Blood Oxygenation and Ozonation EBOO Recuiculatory Haemoperfusion RHP is a procedure, which was developed and used in medical departments with the aim of amplifying the results observed with ozone. Relying confidently on the valid principles of ozone therapy, a medical team endeavored to increase its therapeutic efficacy. More than fifteen-years, that team developed an apparatus that makes it possible to treat large quantities of blood with ozone in an extracorporeal circulation.
We would like to introduce ourselves as one of the largest ozone centers in Malaysia, First to Provide Ground – Breaking Therapy in the Treatment and Prevention of Coronary Artery Disease.
RHP™ has set benchmarks, by its self-recognition in playing the key role in the treatment and Prevention of Coronary Artery Disease. No Cardiologist, Medical Professional, or Coronary Heart Disease Patient can afford to ignore the vital role of RHP™.
As a leader in the discovery, development, manufacture and marketing of RHP™ (Recirculatory Haemoperfusion™), is committed to improving health and well being through innovative treatments, products and services. We share the medical world's goal of bringing safer and more effective products to the market as promptly as possible.
Before we introduce our treatment, products and services, allow us to give a brief intro of ozone therapy which began in 1870 in Germany and is now recognized in more than 25 countries all around the world including Germany, Italy, Japan, Austria, Switzerland, and some states in the US. It in fact is also approved as a Medical Therapy in Cuba and Russia. There are 2,000 ozone clinics in Europe alone.
The therapeutic use of ozone has an excellent safety record and there have been no toxic effects observed from proper clinical use. The use of ozone as a healing adjunct is well established and is being vigorously pursued by many scientists and clinicians. The benefits are predictable and without any side effects. As technology advances, undoubtedly new techniques will enlarge in the scope of the effective use of this versatile modality.
RHP™, the therapeutic ozoniser, an equipment that produces automatically different ozone concentrations in a continuous and reproducible way in all of ozone’s therapeutic range.
It can be used in all ozone medical applications known at present, for example, optic neuropathy, chronic glaucoma, cochleovestibular syndrome, retinitis pigmentosa, senile dementia, sickle cell anemia, sepsis prevention, arthorosis, obliterant arteriopathy, ulcers of the limb, diabetic foot, and radiological contrast in diaphragmatic angiography. In general, in the specialties of ophthalmology, geriatrics, orthopedics, angiology, internal medicine and many more.
RHP™ is the name of this particular type of ozone generator. As the function implies, RHP™ generates ozone upon introduction of medical oxygen into generator. Our procedure, known as RHP™(Recirculatory Haemoperfusion™) is similar to haemodylisis. In this case, RHP™ is born as a remedy to many cardiological problems, without undergoing the threatening high risk, painful, expensive and complicated procedures of surgery.
Specialized ozone therapy centers, on administrating the non- invasive therapy RHP™ to severe coronary artery disease patients, have found amazing results which can be supplied on request.
Through years of extensive research, RHP™ has developed an apparatus called RHP™ that facilitates in treating 3 to 4 liters of blood with medical ozone in extracorporeal circulation for a period of 60 to 90 minutes to patients with coronary heart disease. RHP™ has proven to be second to none in delivering its role in this procedural assay. To achieve satisfactory result, one has to undergo 15 to 35 hours therapy depending on the state of the disease or malady.
RHP™ is performed by withdrawing venous blood and the same blood is infused into an oxygen- ozone gas exchange filter in and upward direction, using a specialized guideline with a computerized peristaltic pump controlling the rate of withdrawal. Medical ozone from RHP™ is introduced into this hydrophobic and ozone resistant gas exchange filter in the opposite direction from top going downwards as ozonation of blood begins. To avoid coagulation during the process of RHP™ treatment, slight heparinazation of the blood is done, this just before the blood is infused into the filter. After passing through the oxygen-ozone gas exchange filter, treated blood is then reinfused to the patient. Upon establishment of extracorporeal circuit, the withdrawal rate will be increased to a range of 60-80 ml per minute, depending on the condition of the patient.
It has been established by various scientific researchers that reinfusion of oxygenated and ozonated blood enhances the release of nitric oxide and interleukin-8 in the human endothelial cells (the layer of cells lining the artery wall).
Achieved results of the therapy in general from various conditions show:
1. Improved Vasodilatation (stretching of a vessel/arteriole beyond its normal dimension leading to increased blood flow) in ischemic areas.
2. Reduced hypoxia (reduction of oxygen carrying capacity of blood)
3. Induced Neoangiogenesis (formation of new blood vessels) due to enhanced release of nitric oxide.
RHP™ is a device-based therapy intended to remove extra fluid from the blood and body; Fluid Extraction as the name implies. Patients with heart failure typically are treated with various medications, including angiotensin-converting enzyme inhibitors, beta-blockers, diuretics, and inotropic drugs. Although these drugs don't stop disease progression, they may reduce symptoms and improve functional capacity. Over time, however, some patients stop responding to these therapies.
Fluid Extraction, a process that removes fluid from the intravascular compartment can help ease symptoms for these patients. It may even help patients respond again to conventional drug therapy.
During Fluid Extraction, the patient intravascular fluid remains stable, as fluid shifts from extravascular space that is lost from the vessels. This reduces edema and third spacing. But because fluid is not removed from the vascular compartment any faster than it can be recruited from the peripheral tissues, patients do not become hypotensive- the plasma refilling rate is adequate to prevent hypovolemia. The patient's heart rate, blood pressure and serum electrolytes also remain largely unchanged.
In general, RHP™ improves the quality of life with the ceasing of anginal pain and increase of functional abilities. We are proud to say that Fluid Extraction is a truly high quality invention by a team of medical experts and engineers.
We would also like to dedicate our sincere appreciation to the 1998 Nobel Prize Winners in Physiology or Medicine for their discoveries concerning nitric oxide as a signaling molecules in the cardiovascular system- Robert F. Furchgott (SUNY Health Science Center Brooklyn, New York, USA), Louis J. Ignarro (University of California School of Medicine) and Ferid Murad (University of Texas) for their discoveries concerning the role of nitric oxide as a signaling molecule in the cardiovascular system. These medical experts have given us the inspiration and encouragement to come up with our invention RHP™ (Recirculatory Haemoperfusion™).
We will be more than happy to assist you in any way possible, either a request for demonstration or merely further queries. Our medical counselors are available daily (except public holidays) for assistance and to answer questions. Research papers are available on demand and we will be glad to provide a more-detailed explanation of the procedures and other related matters.
Please do no hesitate to contact us at:
1. Folkman J. tumour angiogenesis: therapeutic implications. N Eng J Med. 1971; 285:
2.Takeshita S, Zheng LP, Brogi E et al. Therapeutic angiogenesis. Asingle intraarterial
bolus of vascular endothelial growth factor augments revascularization in a rabbit
ischaemic hind limb model. J Clin Invest. 1994; 93: 662-70.
3. Morbidelli L, Chang CH, Douglas HJ, Granger FL and Ziche M. Nitric oxide mediates
mitogenic effect of VEGF on coronary venular endothelium. Am J Physiol 1996;
4. Ziche M, Morbidelli L, Masini S et al. Nitric Oxide mediates angiogenesis in vivo and
endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest.
1994; 94: 2036-2044.
5. Moncada S, Palmer RM and higgs EA. Nitric Oxide: physiology, pathophysiology and
pharmacology. Phamarcol Rev. 1991; 43: 109-142.
6. Hood JD, Meininger CJ, Ziche M et al. VEGF upregulates ecNOS message, protein
and NO production in human endothelial cells. Am J Physiol.1998 ; 274 (3 pt 2):
7. Pepper MS, Mandriota S, Vassalli JD et al. Angiogenesis regulating cytokines:
activities and interactions. Curr Top Microbiol Immunol. 1996; 213:31-67.
8. Henry TD. Science, Medicine, and the future: Therapeutic angiogenesis. BMJ 1999;
9. Isner JM. Tissue responses to ischaemia: local and remote responses for preserving
perfusion in ischaemic muscle. J Clin Invest. 2000; 106: 615- 619.
10. Freedman SB, Isner JM. Therapeutic angiogenesis for coronary artery disease.
Ann Intern Med 2002; 136: 54-71.
11. Giunta R. Ozonized antohaemotransfusion improves haemorheological parameters
and oxygen delivery to tissues in patients with peripheral occlusive disease. Ann
Hematol 2001; 80:745-748.
12. Hernandez F, Menendez S and Wong R Decrease of blood cholesterol and stimulation
antioxidative response in cardiopathy patients treated with endovenous ozone therapy.
Free Radic Biol. Med. 1995; 19:115-119.
13. Rilling S. the basic clinical applications of ozone therapy. Sci Eng. 1985; 7: 259- 274.
14. Valacchi G and Bocci V. Studies on the biological effects of ozone: 6. Production of
transforming growth factor 1 by human blood after ozone treatment. J Biol Regular
Homeost Agent B 1994; 8: 108-112.
15. Bocci V, Luzzi E, Corradeschi F et al. Studies on the biological effects of ozone: 6.
Production of transforming growth factor 1 by human blood after ozone treatment.
J Biol Regular Homeost Agent 1998; 8: 108-112.
16. Paulesu L, Luzzi E, and Bocci B. Studies on the biological effects of ozone: 2.
Induction of tumour necrosis factor (TNF-alpha) on human leukocytes. Lymphokine
And Cytokine Research 1991; 10: 409-412.
17. Bocci V, Valacchi G, Corradeschi F et al. Studies on the bilological effects of ozone:
8. Effects on the total antioxidant status and on interleukin- 8 production. Mediat
Inflamm 1998; 7:313-317.
18. Valacchi G and Bocci V. Studies on the biological effects of ozone: 10. Release of
factors from ozonated human platelets. Mediat Inflamm 1999; 8: 205-209.
19. Laskin DL, Heck DE and Laskin JD. Role of inflammatory cytokines and nitric oxide
in heptic and pulmanory toxicity. Toxicol Lett 1998; 102-103:289-293.
20. Chua CC, Hamdy RC and Chua BHC. Upregulation of vascular endothelial growth
factor by H2O2 in rat heart endothelial cells. Free Rad Biol Med 1998; 25: 891-897.
21. Ernst E. Complementary medicine: from quackery to science? J Lab Clin Med 1996;
22. Bocci V. Biological and clinical effect of ozone. Has ozone therapy any future in
medicine? Brit J Biomed Sci 1999: 56: 270-279.
23. Jaffe EA, Nachman RI, Becker CG, Minick CR. Culture of endothelial cells derived
from umbilical vein. Indentification by morphologic and immunologic criteria
J Clien Invest 1973; 52: 2745-2756.
24. Wong R, Menedez S, Castener J, et al Ozone Therapy in ischaemic cardiopathy. In
Proceedings; Ozone in Medicine. 12th World Congress of the International Ozone
Association, 15-18 May 1995, lilie France, edited by International Ozone Association
Tours. Instaprint, 1995; 73-7.
25. Snyder S. Bredt D: Biological role of Nitric Oxide, Scientific American may 1992; 26
26. Jaffe EA, Nachman RI, Becker CG, Minick CR. Culture of human endothelial cells
derived from umbilical vein. Indentification by morphologic and immunologic criteria
J Clien Invest 1973; 52: 2745-2756.
27. Cartwright JE, Withley GS, Johnstone AP. Endothelial cell adhesion molecule
expression and lymphocyte adhesion to endothelial cells: effect of nitric oxide
Exp Cell Res 1997; 235: 431-434.
28. N. Di Paolo, V Bocci, G Garosi, E. Borelli, A Bravi, A Bruci, Aldinucci, L
Capotondo Extracorporeal Blood Oxygenation and Ozonation (EBOO) in man.
29. Giancarlo, Garzi, Sergio; Giraldi, Francesco; lauri, Gianfranco; Prego,
Giovanbattista; Guazzi, Marco: Salvioni, Allesandro; Guazi, Maurizio D.
The American Journal Medicne, 1993 Experta Medica, Merenzi, Volume 94(1)
January 1993 pp 49-56 Interrelation of Humoral Factors, Haemodynamics, and fluid
and Salt Metabolism in Congestive Heart Failure: Effects of Extracorporeal
30. Rosenthal, Kelli RN, BC , APRN,BC . Nursing 2004, 2004 Lippincott Williams
& Wilkins, Volume 34(4) April 2004 p 17, Using Ultrafiltration to treat heart failure.
31. “Refractory Congestive Heart Failure: Overview and Application of Extracorporeal Ultrafiltration” by Blake and Paganini.Advances in Renal Replacement Therapy, Vol. 3 No. 2 (April), 1996 :pp166
32. “Circulatory Response to Fluid Overload Removal by Extracorporeal Ultrafiltration in Refractory Congestive Heart Failure” by Marenzi et. Al, JACC, Vol 38 , No 4, 2001 (October) :pp963-968
33. “Hemofiltration as Short-Term Treatment of Refractory Congestive Heart Failure” by Rimondini et. Al, .The American Journal of Medicine, Vol 83, July 1987: 43-47
34. “Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency” by Agostoni et. Al, The American Journal of Medicine, 96:191-199, 1994
35. “Apparent paradox of neurohumoral axis inhibition after body fluid volume depletion in patients with chronic congestive heart failure and water retention “ by Guazzi et. Al, British Heart Journal , 1994:72:534-539
36. “American College of Cardiology (Acc) / American Heart Association (AHA ) Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult” document developed in collaboration with the International Society for Heart and Lung Transplantion (ISHLT) and endorsed by the Heart Failure Society of America (HFSA). Approved by ACC Board of Trustees in November 2001 and the AHA Science Advisory and Coordinating Committee in Spetember 2001.